RTOG 0920, “A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer,” is closed to accrual as of 5 PM ET Tuesday, March 27, 2018, because it has reached its accrual target, as broadcast on March 23.


  • All patients registered to Step 1 registration by March 27 will be permitted to proceed to the randomization step (Step 2).
  • Participating sites must record destruction of all drug destroyed on site.  A destruction log provided by McKesson/Biologics is located on the CTSU website and should be returned to McKesson when complete. See protocol section 7 for further details.
  • Data collection and site IRB renewal for closed studies must continue until the study is terminated.

Please distribute this information to the appropriate personnel at participating affiliate/NCORP component institutions.

View this email in your browser
You are receiving this email because of your relationship with NRG Oncology. Please reconfirm your interest in receiving emails from us. If you do not wish to receive any more emails, you can unsubscribe here.
This message was sent from to
Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103

Update Profile/Email Address | Forward Email | Report Abuse